Alexander Berg

421 total citations
20 papers, 332 citations indexed

About

Alexander Berg is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Alexander Berg has authored 20 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Oncology. Recurrent topics in Alexander Berg's work include Tuberculosis Research and Epidemiology (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Drug Transport and Resistance Mechanisms (3 papers). Alexander Berg is often cited by papers focused on Tuberculosis Research and Epidemiology (5 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Drug Transport and Resistance Mechanisms (3 papers). Alexander Berg collaborates with scholars based in United States, United Kingdom and Poland. Alexander Berg's co-authors include Tomás Torroba, Borja Díaz de Greñu, Tobias Nilsson, Daniel Moreno, D. K. Srivastava, Klaus Romero, Debra Hanna, David Hermann, Joel M. Reid and Masoud Jamei and has published in prestigious journals such as Journal of the American Chemical Society, Biochemistry and Biophysical Journal.

In The Last Decade

Alexander Berg

20 papers receiving 325 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexander Berg United States 12 87 82 67 65 53 20 332
Robert T. Koda United States 15 102 1.2× 52 0.6× 51 0.8× 39 0.6× 20 0.4× 35 520
Kevin Knagge United States 11 179 2.1× 108 1.3× 44 0.7× 27 0.4× 25 0.5× 15 433
Martin Kiefer Germany 8 166 1.9× 24 0.3× 40 0.6× 55 0.8× 31 0.6× 10 366
Yuri V. Mezentsev Russia 14 326 3.7× 49 0.6× 21 0.3× 44 0.7× 26 0.5× 58 596
Chiun‐Gung Juo Taiwan 12 141 1.6× 47 0.6× 19 0.3× 61 0.9× 93 1.8× 17 595
Makoto Ono Japan 13 78 0.9× 66 0.8× 26 0.4× 166 2.6× 7 0.1× 38 472
Hayley B. Schultz Australia 11 95 1.1× 60 0.7× 10 0.1× 95 1.5× 8 0.2× 28 393
Dorota G. Piotrowska Poland 18 288 3.3× 39 0.5× 31 0.5× 44 0.7× 124 2.3× 87 947
Heidi M. Hoard-Fruchey United States 9 126 1.4× 57 0.7× 85 1.3× 48 0.7× 15 0.3× 17 368
Daniel L. Parsons United States 11 181 2.1× 70 0.9× 20 0.3× 109 1.7× 31 0.6× 30 549

Countries citing papers authored by Alexander Berg

Since Specialization
Citations

This map shows the geographic impact of Alexander Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Berg more than expected).

Fields of papers citing papers by Alexander Berg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Berg. The network helps show where Alexander Berg may publish in the future.

Co-authorship network of co-authors of Alexander Berg

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Berg. A scholar is included among the top collaborators of Alexander Berg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Berg. Alexander Berg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berg, Alexander, et al.. (2024). Time delay and evidence profiles forming clinical recommendations of US surgical society guidelines. Surgery. 178. 108916–108916. 1 indexed citations
2.
Gumbo, Tawanda, Shashikant Srivastava, Devyani Deshpande, et al.. (2023). Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development. Journal of Antimicrobial Chemotherapy. 78(4). 953–964. 7 indexed citations
3.
Kriel, Belinda, Laura E. Via, Yin Cai, et al.. (2022). Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts. BMC Infectious Diseases. 22(1). 327–327. 11 indexed citations
4.
Almond, Lisa M., Alexander Berg, Iain Gardner, et al.. (2021). Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs. CPT Pharmacometrics & Systems Pharmacology. 10(11). 1382–1395. 11 indexed citations
5.
Mallikaarjun, Suresh, Moti Chapagain, T. Sasaki, et al.. (2020). Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 65(1). 17 indexed citations
6.
Srivastava, Shashikant, Devyani Deshpande, Gesham Magombedze, et al.. (2019). Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. Journal of Antimicrobial Chemotherapy. 75(2). 392–399. 14 indexed citations
7.
Polak, Sebastian, Klaus Romero, Alexander Berg, et al.. (2018). Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 457–467. 18 indexed citations
8.
Patel, Nikunjkumar, Oliver Hatley, Alexander Berg, et al.. (2018). Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. The AAPS Journal. 20(3). 47–47. 12 indexed citations
9.
10.
Berg, Alexander, Jan C. Buckner, Evanthia Galanis, et al.. (2015). Quantification of the impact of enzyme‐inducing antiepileptic drugs on irinotecan pharmacokinetics and SN‐38 exposure. The Journal of Clinical Pharmacology. 55(11). 1303–1312. 18 indexed citations
11.
Greñu, Borja Díaz de, et al.. (2014). Fluorescent Discrimination between Traces of Chemical Warfare Agents and Their Mimics. Journal of the American Chemical Society. 136(11). 4125–4128. 122 indexed citations
12.
Berg, Alexander, Sumithra J. Mandrekar, Katie L. Allen Ziegler, et al.. (2013). Population Pharmacokinetic Model for Cancer Chemoprevention With Sulindac in Healthy Subjects. The Journal of Clinical Pharmacology. 53(4). 403–412. 16 indexed citations
13.
14.
15.
Sylvester, Robert, et al.. (2010). Temozolomide-induced severe myelosuppression. Anti-Cancer Drugs. 22(1). 104–110. 17 indexed citations
16.
Berg, Alexander, et al.. (2009). Solvent-assisted slow conversion of a dithiazole derivative produces a competitive inhibitor of peptide deformylase. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1804(4). 704–713. 8 indexed citations
17.
Berg, Alexander & D. K. Srivastava. (2009). Delineation of Alternative Conformational States in Escherichia coli Peptide Deformylase via Thermodynamic Studies for the Binding of Actinonin. Biochemistry. 48(7). 1584–1594. 9 indexed citations
18.
Berg, Alexander, et al.. (2008). Modulation of Ligand Binding Affinity of Tumorigenic Carbonic Anhydrase XII Upon Interaction with Cationic CdTe Quantum Dots. Journal of Biomedical Nanotechnology. 4(4). 491–498. 8 indexed citations
19.
Berg, Alexander, et al.. (2007). Energetic rationale for an unexpected and abrupt reversal of guanidinium chloride‐induced unfolding of peptide deformylase. Protein Science. 17(1). 11–15. 4 indexed citations
20.
Almeida, Paulo F., et al.. (2006). The Cooperative Response of Synaptotagmin I C2A. A Hypothesis for a Ca2+-Driven Molecular Hammer. Biophysical Journal. 92(4). 1409–1418. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert T. Koda Breakdown of academic impact, for papers by Kevin Knagge Breakdown of academic impact, for papers by Martin Kiefer Breakdown of academic impact, for papers by Yuri V. Mezentsev Breakdown of academic impact, for papers by Chiun‐Gung Juo Breakdown of academic impact, for papers by Makoto Ono Breakdown of academic impact, for papers by Hayley B. Schultz Breakdown of academic impact, for papers by Dorota G. Piotrowska Breakdown of academic impact, for papers by Heidi M. Hoard-Fruchey Breakdown of academic impact, for papers by Daniel L. Parsons
Rankless by CCL
2026